TP53 and leukemia: When evaluating leukemia-free survival (LFS), EZH2 (HR 8.49, 95% CI 1.85–39.02, p = 0.006) and TP53 mutations (HR 6.24, 1.63–23.86, p = 0.007) predicted for shorter LFS.